{"groups":[{"description":"This was the only treatment arm in the study. Up to 8 participants were to receive a single oral dose of 200 mg containing approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib, 30 minutes after starting a standard high-fat breakfast.\n\nBemcentinib: Each 200 mg dose contained approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and was administered as a single dose on Day 1 of the study.","id":"FG000","title":"Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were screened to the inclusion/exclusion criteria of the protocol. The following assessments were performed: Informed Consent, Demographics, Medical History, Height \\& Weight, ECG, Vital Signs and Safety Laboratory Testing/Urinalysis \\& Drugs of Abuse testing.","recruitmentDetails":"Study recruitment was undertaken in the United Kingdom at a single site. The recruitment process began in August 2022 and concluded in September 2022. A sufficient number of volunteers were screened in order to successfully recruit 6 eligible participants."}